Evidence map›Paper›PMID 37547456›Full record

ReviewRSC chemical biology2023

P

Louise A Stubbing, Jonathan G Hubert, Joseph Bell-Tyrer, Yann O Hermant, Sung Hyun Yang, Alice M McSweeney, Geena M McKenzie-Goldsmith, Vernon K Ward, Daniel P Furkert, Margaret A Brimble

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in RSC chemical biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Frontiers in pharmacology · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Louise A StubbingSchool of Chemical Sciences, The University of Auckland 23 Symonds Street and 3b Symonds Street Auckland 1142 New Zealand m.brimble@auckland.ac.nz.
Jonathan G HubertSchool of Chemical Sciences, The University of Auckland 23 Symonds Street and 3b Symonds Street Auckland 1142 New Zealand m.brimble@auckland.ac.nz.
Joseph Bell-TyrerSchool of Chemical Sciences, The University of Auckland 23 Symonds Street and 3b Symonds Street Auckland 1142 New Zealand m.brimble@auckland.ac.nz.
Yann O HermantSchool of Chemical Sciences, The University of Auckland 23 Symonds Street and 3b Symonds Street Auckland 1142 New Zealand m.brimble@auckland.ac.nz.ORCID https://orcid.org/0000-0002-3735-7703
Sung Hyun YangSchool of Chemical Sciences, The University of Auckland 23 Symonds Street and 3b Symonds Street Auckland 1142 New Zealand m.brimble@auckland.ac.nz.
Alice M McSweeneyMaurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland 3b Symonds Street Auckland 1142 New Zealand.
Geena M McKenzie-GoldsmithMaurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland 3b Symonds Street Auckland 1142 New Zealand.
Vernon K WardMaurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland 3b Symonds Street Auckland 1142 New Zealand.ORCID https://orcid.org/0000-0001-8692-5116
Daniel P FurkertSchool of Chemical Sciences, The University of Auckland 23 Symonds Street and 3b Symonds Street Auckland 1142 New Zealand m.brimble@auckland.ac.nz.ORCID https://orcid.org/0000-0001-6286-9105
Margaret A BrimbleSchool of Chemical Sciences, The University of Auckland 23 Symonds Street and 3b Symonds Street Auckland 1142 New Zealand m.brimble@auckland.ac.nz.ORCID https://orcid.org/0000-0002-7086-4096

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Viral infections are one of the leading causes of acute morbidity in humans and much endeavour has been made by the synthetic community for the development of drugs to treat associated diseases. Peptide-based enzyme inhibitors, usually short sequences of three or four residues, are one of the classes of compounds currently under development for enhancement of their activity and pharmaceutical properties. This review reports the advances made in the design of inhibitors targeting the family of highly conserved viral proteases 3C/3CL

Identifiers

PMID37547456
PMCPMC10398354

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.